Compare Chevron Corp (CVX) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chevron Corp vs Enveric Biosciences Inc — how do they compare? Chevron Corp trades at $210.38 (market cap $402.42B), while Enveric Biosciences Inc trades at $1.51 (market cap $6.69M). The key difference: Chevron Corp is far larger — about 60152.5× Enveric Biosciences Inc's market cap, and Chevron Corp pays a 3.47% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Chevron Corp for 101 Days and Enveric Biosciences Inc for 14 Days on average.
| CVX | ENVB | |
|---|---|---|
Market Cap | $402.42B | $6.69M |
Volume | 5,699,721 | 41,141 |
Sector | Energy | Health |
52-Week High | $217.73 | $10.80 |
52-Week Low | $146.72 | $1.27 |
Typical Hold Time | 101 Days | 14 Days |
Enterprise Value | $430.97B | -$1.60M |
Dividend Yield | 3.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVX trades at $211.605, up 1.92% today, with a neutral technical signal. The stock shows strong earnings beats in recent quarters, with Q2 2026 EPS of $6.06 exceeding the $5.55 estimate. Revenue for 2025 was $184.43B, though net income declined to $12.30B. Analyst consensus is bullish with a $208.31 price target and 62% buy ratings. Recent news highlights Chevron's $13.8B investment in Argentina's Vaca Muerta and geopolitical impacts on oil prices.
The outlook for CVX is supported by high oil prices and strategic investments, but risks include volatile energy markets and declining profit margins. Earnings growth and dividend stability remain key catalysts, though geopolitical tensions and operational execution pose challenges for sustained shareholder returns.
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chevron Corp
Chevron Corporation is an integrated energy company with operations in countries located around the world. The Company produces and transports crude oil and natural gas. Chevron also refines, markets, and distributes fuels, as well as is involved in chemical and mining operations, power generation, and energy services.
Read more on CVX →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
